Evidence map›Paper›PMID 30009488›Full record

ArticleClinical and experimental immunology2018

Dendritic cells cross-talk with tumour antigen-specific CD8

Y Eiraku, H Terunuma, M Yagi, X Deng, A J Nicol, M Nieda

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  4. Article
  5. Article
  6. Advanced T and Natural Killer Cell Therapy for Glioblastoma.Journal of Korean Neurosurgical Society · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Y EirakuBiotherapy Institute of Japan, Tokyo, Japan.
H TerunumaBiotherapy Institute of Japan, Tokyo, Japan.
M YagiBiotherapy Institute of Japan, Tokyo, Japan.
X DengBiotherapy Institute of Japan, Tokyo, Japan.
A J NicolUniversity of Queensland, Greenslopes Private Hospital, Brisbane, QLD, Australia.
M NiedaBiotherapy Institute of Japan, Tokyo, Japan.ORCID 0000-0003-1682-6360
Biotherapy Institute of Japan · JPThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The finding that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs for developing more effective vaccines for DC therapy. The expression of cytomegalovirus (CMV) antigens in glioblastoma multiforme (GBM) presents a unique opportunity to target these viral proteins for tumour immunotherapy. Here, we demonstrate that Vγ9γδT cells, innate immune cells activated by zoledronate (Z) and Vα24 natural killer (Vα24NK) cells, innate/adaptive immune cells activated by α-galactosylceramide (G) can link innate and adaptive immunities through cross-talk with interferon (IFN) DCs from patients with glioblastoma multiforme (GBM) and healthy donors in a manner that can amplify the activation and proliferation of CMVpp65-specific CD8

Indexed as

Antigens, NeoplasmB7-H1 AntigenCytomegalovirusDendritic CellsGalactosylceramidesGlioblastomaGranulocyte-Macrophage Colony-Stimulating FactorHumansImmunotherapyInterferon-alphaIntraepithelial LymphocytesLymphocyte ActivationNatural Killer T-CellsPhosphoproteinsProgrammed Cell Death 1 Ligand 2 ProteinT-Lymphocytes, Cytotoxicalpha-galactosylceramideAntigens, NeoplasmB7-H1 AntigenCD274 protein, humanCSF2 protein, humancytomegalovirus matrix protein 65kDaGalactosylceramidesGranulocyte-Macrophage Colony-Stimulating FactorIFNA1 protein, humanInterferon-alphaPDCD1LG2 protein, humanPhosphoproteinsProgrammed Cell Death 1 Ligand 2 ProteinViral Matrix ProteinsZoledronic Acidalpha-galactosylceramideCMVpp65-specific CD8+ T cellscytomegalovirus (CMV)pp65glioblastoma multiformezoledronate

Identifiers

PMID30009488
PMCPMC6156812
OpenAlexW2884699001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.